Table 1 Maternal and fetal prognosis in pregnancy after breast cancer treatment in carriers of BRCA1/2 pathogenic variants
From: Pregnancy after breast cancer in BRCA1/2 mutation carriers
Reference | Number of patients | Median age at diagnosis, years | Breast cancer treatment | Median age at birth, years | Maternal prognosis | Delivery complications, % | Birth defects in fetus, % |
|---|---|---|---|---|---|---|---|
195 | 30 | Chemotherapy in 94.4% (anthracycline and/or taxane in 96,7%); Hormone therapy in 91% (Tamoxifen and/or GnRHa in 84,7%) | 35.7 | No impact | 11.6, no impact | 1.8, no impact | |
53 | 32.5 | Chemotherapy in 83.5%; Tamoxifen in 16.7% | 35 | No impact | Not evaluated | Not evaluated |